Natural compounds proposed for the management of non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease; Natural compounds; Sylimarin; Curcumin; Biochanin A; Oleanolic acid; Ginsenoside K; 6-Gingerol; Naringenin; Hesperidin; Chenopodium quinoa

Abstract :

[en] Although non‐alcoholic fatty liver disease (NAFLD) presents as an intricate condition characterized by a growing prevalence, the often‐recommended lifestyle interventions mostly lack high‐level evidence of efficacy and there are currently no effective drugs proposed for this indication. The present review delves into NAFLD pathology, its diverse underlying physiopathological mechanisms and the available in vitro, in vivo, and clinical evidence regarding the use of natural compounds for its management, through three pivotal targets (oxidative stress, cellular inflammation, and insulin resistance). The promising perspectives that natural compounds offer for NAFLD management underscore the need for additional clinical and lifestyle intervention trials. Encouraging further research will contribute to estab‐ lishing more robust evidence and practical recommendations tailored to patients with varying NAFLD grades.

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Merenda, Théodora ; Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Pharmacie Clinique

Juszczak, Florian ; Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service de Biochimie métabolique et moléculaire

Ferier, Elisabeth ; Université de Mons - UMONS > Faculté des Sciences > Service de Physique des matériaux et Optique

Duez, Pierre ; Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service de Chimie thérapeutique et Pharmacognosie

Patris, Stéphanie ; Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Pharmacie Clinique

Decleves, Anne-Emilie ; Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service de Biochimie métabolique et moléculaire

Nachtergael, Amandine ; Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service de Chimie thérapeutique et Pharmacognosie

Language :

English

Title :

Natural compounds proposed for the management of non-alcoholic fatty liver disease

Publication date :

01 April 2024

Journal title :

Natural Products and Bioprospecting

ISSN :

2192-2195

eISSN :

2192-2209

Publisher :

SpringerOpen, Germany

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Research unit :

M110 - Pharmacie Clinique

Research institute :

R550 - Institut des Sciences et Technologies de la Santé

Data Set :

https://doi.org/10.1007/s13659-024-00445-z

Available on ORBi UMONS :

since 08 April 2024

Statistics

Number of views

172 (3 by UMONS)

Number of downloads

105 (1 by UMONS)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

J. George Q. Anstee V. Ratziu A. Sanyal NAFLD: the evolving landscape J Hepatol 2018 68 2 227 229 29223512 10.1016/j.jhep.2017.11.016
J.M. Pappachan S. Babu B. Krishnan N.C. Ravindran Non-alcoholic fatty liver disease: a clinical update J Clin Transl Hepatol 2017 5 4 384 393 29226105 5719196
Z.M. Younossi P. Golabi J.M. Paik A. Henry C. Van Dongen L. Henry The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review Hepatology 2023 77 4 1335 1347 36626630 10.1097/HEP.0000000000000004
M. Eslam P.N. Newsome S.K. Sarin Q.M. Anstee G. Targher M. Romero-Gomez et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement J Hepatol 2020 73 1 202 209 32278004 10.1016/j.jhep.2020.03.039
R. Anty P. Gual Physiopathologie des stéatoses hépatiques métaboliques Presse Med 2019 48 12 1468 1483 31767252 10.1016/j.lpm.2019.09.051
EASL EASD EASO EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease J Hepatol 2016 64 6 1388 1402 10.1016/j.jhep.2015.11.004
Z.M. Younossi A.B. Koenig D. Abdelatif Y. Fazel L. Henry M. Wymer Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 2016 64 1 73 84 26707365 10.1002/hep.28431
L. Rong J. Zou W. Ran X. Qi Y. Chen H. Cui et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD) Front Endocrinol 2023 13 1087260 10.3389/fendo.2022.1087260
M. Chauhan K. Singh P.J. Thuluvath Bariatric surgery in NAFLD Dig Dis Sci 2022 67 2 408 422 34981313 10.1007/s10620-021-07317-3
N. Chalasani Z. Younossi J.E. Lavine M. Charlton K. Cusi M. Rinella et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases Hepatology 2018 67 1 328 357 28714183 10.1002/hep.29367
P. Bedossa Pathology of non-alcoholic fatty liver disease Liver Int 2017 37 S1 85 89 28052629 10.1111/liv.13301
E. Elsheikh L.L. Henry Z.M. Younossi Current management of patients with nonalcoholic fatty liver disease Expert Rev Endocrinol Metab 2013 8 6 549 558 1:CAS:528:DC%2BC3sXhs12lsrrF 30736139 10.1586/17446651.2013.846212
J. Boursier O. Mueller M. Barret M. Machado L. Fizanne F. Araujo-Perez et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota Hepatology 2016 63 3 764 775 1:CAS:528:DC%2BC28XjsFejtbo%3D 26600078 10.1002/hep.28356
Dehnavi Z, Razmpour F, Belghaisi Naseri M, Nematy M, Alamdaran SA, Vatanparast HA, et al. Fatty liver index (FLI) in predicting non-alcoholic fatty liver disease (NAFLD). Hepat Mon. 2018;18(2). https://doi.org/10.5812/hepatmon.63227
Z. Younossi Q.M. Anstee M. Marietti T. Hardy L. Henry M. Eslam et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Nat Rev Gastroenterol Hepatol 2018 15 1 11 20 28930295 10.1038/nrgastro.2017.109
J. Li B. Zou Y.H. Yeo Y. Feng X. Xie D.H. Lee et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis Lancet Gastroenterol Hepatol 2019 4 5 389 398 30902670 10.1016/S2468-1253(19)30039-1
H. Devarbhavi S.K. Asrani J.P. Arab Y.A. Nartey E. Pose P.S. Kamath Global burden of liver disease: 2023 update J Hepatol 2023 79 2 516 537 36990226 10.1016/j.jhep.2023.03.017
F. Zhou J. Zhou W. Wang X. Zhang Y. Ji P. Zhang et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis Hepatology 2019 70 4 1119 1133 31070259 10.1002/hep.30702
V. Kupčová M. Fedelešová J. Bulas P. Kozmonová L. Turecký Overview of the pathogenesis, genetic, and non-invasive clinical, biochemical, and scoring methods in the assessment of NAFLD Int J Environ Res Public Health 2019 16 19 3570 31554274 6801903 10.3390/ijerph16193570
B. Van De Wier G.H. Koek A. Bast G.R.M.M. Haenen The potential of flavonoids in the treatment of non-alcoholic fatty liver disease Crit Rev Food Sci Nutr 2017 57 4 834 855 25897647 10.1080/10408398.2014.952399
C. Robichon J. Girard C. Postic L’hyperactivité de la lipogenèse peut-elle conduire à la stéatose hépatique?: Implication du facteur de transcription ChREBP Médecine/Sciences 2008 24 10 841 846 18950580 10.1051/medsci/20082410841
H. Zeng H. Qin M. Liao E. Zheng X. Luo A. Xiao et al. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing Mol Metab 2022 57 1:CAS:528:DC%2BB38XhtFOqtL0%3D 34974159 10.1016/j.molmet.2021.101428
D.H. Van Raalte M. Li P.H. Pritchard K.M. Wasan Peroxisome proliferator-activated receptor (PPAR): a pharmacological target with a promising future Pharm Res 2004 21 9 1531 1538 15497675 10.1023/B:PHAM.0000041444.06122.8d
H. Malhi G. Gores Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Semin Liver Dis 2008 28 04 360 369 1:CAS:528:DC%2BD1cXhsVKju7fF 18956292 2908270 10.1055/s-0028-1091980
L. Rohit L.F. Scott I.S. Gerald Mechanisms and disease consequences of non-alcoholic fatty liver disease Cell 2021 184 10 2537 2564 10.1016/j.cell.2021.04.015
J. Aron-Wisnewsky M.V. Warmbrunn M. Nieuwdorp K. Clément Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? Gastroenterology 2020 158 7 1881 1898 1:CAS:528:DC%2BB3cXosVaisLs%3D 32044317 10.1053/j.gastro.2020.01.049
X. Hongtao Xu F. Fang W. Kaizhang Wu J. Song Y. Li L. Xingyu Lu J. Liu L. Zhou Y. Wenqing Yu Y. Fei Yu J. Gao Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia Microbiome 2023 11 1 262 10.1186/s40168-023-01709-5
Y.K. Zhao X.D. Zhu R. Liu X. Yang Y.L. Liang Y. Wang The role of PPARγ gene polymorphisms, gut microbiota in type 2 diabetes: current progress and future prospects Diabetes Metab Syndr Obes Targets Ther 2023 16 3557 3566 1:CAS:528:DC%2BB3sXisVSqsrrJ 10.2147/DMSO.S429825
C. Di Rosa L. Di Francesco C. Spiezia Y.M. Khazrai Effects of animal and vegetable proteins on gut microbiota in subjects with overweight or obesity Nutrients 2023 15 12 2675 37375578 10300930 10.3390/nu15122675
C. Saponaro M. Gaggini A. Gastaldelli Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms Curr Diab Rep 2015 15 6 34 10.1007/s11892-015-0607-4
S. Romeo J. Kozlitina C. Xing A. Pertsemlidis D. Cox L.A. Pennacchio et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat Genet 2008 40 12 1461 1465 1:CAS:528:DC%2BD1cXhsVWgsrrP 18820647 2597056 10.1038/ng.257
R.S. Basu PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease Adipocyte 2019 8 1 201 208 10.1080/21623945.2019.1607423
S. He C. McPhaul J.Z. Li R. Garuti L. Kinch N.V. Grishin et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis* J Biol Chem 2010 285 9 6706 6715 1:CAS:528:DC%2BC3cXit1aitrg%3D 20034933 10.1074/jbc.M109.064501
Y. Huang S. He J.Z. Li Y.K. Seo T.F. Osborne J.C. Cohen et al. A feed-forward loop amplifies nutritional regulation of PNPLA3 Proc Natl Acad Sci 2010 107 17 7892 7897 1:CAS:528:DC%2BC3cXlsFynt7w%3D 20385813 2867902 10.1073/pnas.1003585107
A.C. Lake Y. Sun J.L. Li J.E. Kim J.W. Johnson D. Li et al. Expression, regulation, and triglyceride hydrolase activity of adiponutrin family members J Lipid Res 2005 46 11 2477 2487 1:CAS:528:DC%2BD2MXhtF2iu7nP 16150821 10.1194/jlr.M500290-JLR200
Z. Chamoun F. Vacca R.G. Parton J. Gruenberg PNPLA3/adiponutrin functions in lipid droplet formation Biol Cell 2013 105 5 219 233 1:CAS:528:DC%2BC3sXhtVyjsbbL 23398201 10.1111/boc.201200036
H. Ruhanen J. Perttilä M. Hölttä-Vuori Y. Zhou H. Yki-Järvinen E. Ikonen et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling J Lipid Res 2014 55 4 739 746 1:CAS:528:DC%2BC2cXlt1Slt7c%3D 24511104 3966707 10.1194/jlr.M046607
T. Jelenik K. Kaul G. Séquaris U. Flögel E. Phielix J. Kotzka et al. Mechanisms of insulin resistance in primary and secondary nonalcoholic fatty liver Diabetes 2017 66 8 2241 2253 1:CAS:528:DC%2BC2sXhvFKltrbL 28490610 5521856 10.2337/db16-1147
G. Musso M. Cassader R. Gambino PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease Hepatology 2015 62 2 658 659 25482317 10.1002/hep.27643
P. Farzanegi A. Dana Z. Ebrahimpoor M. Asadi M.A. Azarbayjani Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation Eur J Sport Sci 2019 19 7 994 1003 30732555 10.1080/17461391.2019.1571114
M.J. Oza Y.A. Kulkarni Biochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes Biomed Pharmacother 2018 107 1119 1127 1:CAS:528:DC%2BC1cXhsF2ltLvE 30257324 10.1016/j.biopha.2018.08.073
H. Ohtaki Irisin Handbook of hormones 2016 Amsterdam Elsevier 329-e37-3
S. Zelber-Sagi F. Salomone L. Mlynarsky The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms Liver Int 2017 37 7 936 949 1:CAS:528:DC%2BC2sXhtVKisbnK 28371239 10.1111/liv.13435
R. Belfort S.A. Harrison K. Brown C. Darland J. Finch J. Hardies et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 2006 355 22 2297 2307 1:CAS:528:DC%2BD28Xht1OrtrvI 17135584 10.1056/NEJMoa060326
S. Singh R. Khera A. Allen M.H. Murad R. Loomba Comparative effectiveness of pharmacological interventions for non-alcoholic steatohepatitis: a systematic review and network meta-analysis Hepatology 2015 62 5 1417 1432 1:CAS:528:DC%2BC2MXhslegt7nE 26189925 10.1002/hep.27999
M.J. Armstrong P. Gaunt G.P. Aithal D. Barton D. Hull R. Parker et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Lancet 2016 387 10019 679 690 1:CAS:528:DC%2BC2MXhvVygsbzK 26608256 10.1016/S0140-6736(15)00803-X
M. Ekstedt L.E. Franzén U.L. Mathiesen M. Holmqvist G. Bodemar S. Kechagias Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study J Hepatol 2007 47 1 135 141 1:CAS:528:DC%2BD2sXmtVahtL8%3D 17400325 10.1016/j.jhep.2007.02.013
F. Nassir NAFLD: mechanisms, treatments, and biomarkers Biomolecules 2022 12 6 824 1:CAS:528:DC%2BB38Xhs1ehsLvL 35740949 9221336 10.3390/biom12060824
B.A. Neuschwander-Tetri R. Loomba A.J. Sanyal J.E. Lavine M.L. Van Natta M.F. Abdelmalek et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 2015 385 9972 956 965 1:CAS:528:DC%2BC2cXhvV2gtr%2FE 25468160 10.1016/S0140-6736(14)61933-4
A.J. Sanyal N. Chalasani K.V. Kowdley A. McCullough A.M. Diehl N.M. Bass et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 2010 362 18 1675 1685 1:CAS:528:DC%2BC3cXls1Oltr4%3D 20427778 2928471 10.1056/NEJMoa0907929
S. Raza Current treatment paradigms and emerging therapies for NAFLD/NASH Front Biosci 2021 26 2 206 237 1:CAS:528:DC%2BB3MXivVWrtrbP 10.2741/4892
C.K. Argo J.T. Patrie C. Lackner T.D. Henry E.E. de Lange A.L. Weltman et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial J Hepatol 2015 62 1 190 197 1:CAS:528:DC%2BC2cXhslyksLbJ 25195547 10.1016/j.jhep.2014.08.036
H.M. Parker N.A. Johnson C.A. Burdon J.S. Cohn H.T. O’Connor J. George Omega-3 supplementation, and non-alcoholic fatty liver disease: a systematic review and meta-analysis J Hepatol 2012 56 4 944 951 1:CAS:528:DC%2BC38XktlaqtLk%3D 22023985 10.1016/j.jhep.2011.08.018
A.J. Sanyal M.F. Abdelmalek A. Suzuki O.W. Cummings M. Chojkier EPE-A Study Group No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial Gastroenterology 2014 147 2 377 384.e1 1:CAS:528:DC%2BC2cXhtFyhur3M 24818764 10.1053/j.gastro.2014.04.046
D.B. Jump K.A. Lytle C.M. Depner S. Tripathy Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease Pharmacol Ther 2018 181 108 125 1:CAS:528:DC%2BC2sXht1yrs7rO 28723414 10.1016/j.pharmthera.2017.07.007
V. Šmíd K. Dvořák P. Šedivý V. Kosek M. Leníček M. Dezortová et al. Effect of omega-3 polyunsaturated fatty acids on lipid metabolism in patients with metabolic syndrome and NAFLD Hepatol Commun 2022 6 6 1336 1349 35147302 9134818 10.1002/hep4.1906
P. Campbell A. Symonds A.S. Barritt Therapy for nonalcoholic fatty liver disease: current options and future directions Clin Ther 2021 43 3 500 517 1:CAS:528:DC%2BB3MXpsF2jsLc%3D 33583577 10.1016/j.clinthera.2021.01.021
G. Bower T. Toma L. Harling L.R. Jiao E. Efthimiou A. Darzi et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology Obes Surg 2015 25 12 2280 2289 25917981 10.1007/s11695-015-1691-x
M. Léveillé J.L. Estall Mitochondrial dysfunction in the transition from NASH to HCC Metabolites 2019 9 10 233 31623280 6836234 10.3390/metabo9100233
E. Bugianesi S. Moscatiello M.F. Ciaravella G. Marchesini Insulin resistance in nonalcoholic fatty liver disease Curr Pharm Des 2010 16 17 1941 1951 1:CAS:528:DC%2BC3cXot1ClsL4%3D 20370677 10.2174/138161210791208875
V. Bala S. Rajagopal D.P. Kumar A.D. Nalli S. Mahavadi A.J. Sanyal et al. Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-Îµ pathway and modulated by endogenous H2S Front Physiol 2014 5 420 25404917 4217307 10.3389/fphys.2014.00420
C. Xue Y. Li H. Lv L. Zhang C. Bi N. Dong et al. Oleanolic acid targets the gut-liver axis to alleviate metabolic disorders and hepatic steatosis J Agric Food Chem 2021 69 28 7884 7897 1:CAS:528:DC%2BB3MXhsFWnt7rF 34251802 10.1021/acs.jafc.1c02257
H. Park H.J. Hur S. Kim S. Park M.J. Hong M.J. Sung et al. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice Mol Nutr Food Res 2016 60 9 1944 1955 1:CAS:528:DC%2BC28XptlCms7k%3D 27145114 10.1002/mnfr.201500689
Y. Fan L.T. Yan Z. Yao G.Y. Xiong Biochanin A regulates cholesterol metabolism further delays the progression of nonalcoholic fatty liver disease Diabetes Metab Syndr Obes 2021 14 3161 3172 34276221 8277457 10.2147/DMSO.S315471
M. Mueller B. Lukas J. Novak T. Simoncini A.R. Genazzani A. Jungbauer Oregano: a source for peroxisome proliferator-activated receptor γ antagonists J Agric Food Chem 2008 56 24 11621 11630 1:CAS:528:DC%2BD1cXhsVShsbzK 19053389 10.1021/jf802298w
P. Shen M.H. Liu T.Y. Ng Y.H. Chan E.L. Yong Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARα, PPARγ, and adipocyte differentiation in vitro J Nutr 2006 136 4 899 905 1:CAS:528:DC%2BD28XjtVOks7o%3D 16549448 10.1093/jn/136.4.899
M. Mueller A. Jungbauer Red clover extract: a putative source for simultaneous treatment of menopausal disorders and the metabolic syndrome Menopause 2008 15 6 1120 1131 18724264 10.1097/gme.0b013e31817062ce
L. Wang B. Waltenberger E.M. Pferschy-Wenzig M. Blunder X. Liu C. Malainer et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review Biochem Pharmacol 2014 92 1 73 89 1:CAS:528:DC%2BC2cXht1ymtbjK 25083916 4212005 10.1016/j.bcp.2014.07.018
M. Murgueitio G. Wolber L. Christensen Identification of PPARγ agonists from natural sources using different in silico approaches Planta Med 2014 81 06 488 494 25251562 10.1055/s-0034-1383119
R. Harini M. Ezhumalai K.V. Pugalendi Antihyperglycemic effect of biochanin A, a soy isoflavone, on streptozotocin-diabetic rats Eur J Pharmacol 2012 676 1–3 89 94 1:CAS:528:DC%2BC38Xks1Gksw%3D%3D 22178203 10.1016/j.ejphar.2011.11.051
L. Wu C. Guo J. Wu Therapeutic potential of PPARγ natural agonists in liver diseases J Cell Mol Med 2020 24 5 2736 2748 32031298 7077554 10.1111/jcmm.15028
D.J. Den Hartogh A. Gabriel E. Tsiani Antidiabetic properties of curcumin I: evidence from in vitro studies Nutrients 2020 12 1 118 10.3390/nu12010118
N.M. Abd El-Hameed S.A. Abd El-Aleem M.A. Khattab A.H. Ali H.H. Mohammed Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH) Life Sci 2021 285 1:CAS:528:DC%2BB3MXitFKit7%2FP 34599938 10.1016/j.lfs.2021.119983
S. Saadati A. Sadeghi A. Mansour Z. Yari H. Poustchi M. Hedayati et al. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial BMC Gastroenterol 2019 19 1 133 31345163 6659284 10.1186/s12876-019-1055-4
S. Saadati B. Hatami Z. Yari M.A. Shahrbaf S. Eghtesad A. Mansour et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease Eur J Clin Nutr 2019 73 3 441 449 1:CAS:528:DC%2BC1MXhtV2is7jM 30610213 10.1038/s41430-018-0382-9
Y. Zeng Y. Luo L. Wang K. Zhang J. Peng G. Fan Therapeutic effect of curcumin on metabolic diseases: evidence from clinical studies Int J Mol Sci 2023 24 4 3323 1:CAS:528:DC%2BB3sXksF2iu7w%3D 36834734 9959718 10.3390/ijms24043323
C. Schiborr A. Kocher D. Behnam J. Jandasek S. Toelstede J. Frank The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes Mol Nutr Food Res 2014 58 3 516 527 1:CAS:528:DC%2BC2cXkvFOqsg%3D%3D 24402825 10.1002/mnfr.201300724
G. Shoba D. Joy T. Joseph M. Majeed R. Rajendran P.S. Srinivas Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers Planta Med 1998 64 4 353 356 1:CAS:528:DyaK1cXjtFGhtrg%3D 9619120 10.1055/s-2006-957450
S. Sancilio M. Basile R. Di Pietro Curcuma longa hepatotoxicity: a baseless accusation. Case assessed for causality using RUCAM method Front Pharmacol 2021 12 34776989 8586077 10.3389/fphar.2021.780330
S.A. Almatroodi A.M. Alnuqaydan A.Y. Babiker M.A. Almogbel A.A. Khan R.A. Husain 6-Gingerol, a bioactive compound of ginger attenuates renal damage in streptozotocin-induced diabetic rats by regulating the oxidative stress and inflammation Pharmaceutics 2021 13 3 317 1:CAS:528:DC%2BB3MXhvF2gtL7J 33670981 7997342 10.3390/pharmaceutics13030317
Y. Liu D. Li S. Wang Z. Peng Q. Tan Q. He et al. 6-Gingerol ameliorates hepatic steatosis, inflammation and oxidative stress in high-fat diet-fed mice through activating LKB1/AMPK signaling Int J Mol Sci 2023 24 7 6285 1:CAS:528:DC%2BB3sXotVKhsLc%3D 37047258 10094681 10.3390/ijms24076285
B. Gross M. Pawlak P. Lefebvre B. Staels PPARs in obesity induced T2DM, dyslipidaemia and NAFLD Nat Rev Endocrinol 2017 13 1 36 49 1:CAS:528:DC%2BC28XhsFSgur3F 27636730 10.1038/nrendo.2016.135
T.F. Tzeng S.S. Liou C.J. Chang I.M. Liu [6]-Gingerol dampens hepatic steatosis and inflammation in experimental nonalcoholic steatohepatitis Phytomedicine 2015 22 4 452 461 1:CAS:528:DC%2BC2MXjs1yjsLc%3D 25925967 10.1016/j.phymed.2015.01.015
H. Gao T. Guan C. Li G. Zuo J. Yamahara J. Wang et al. Treatment with ginger ameliorates fructose-induced Fatty liver and hypertriglyceridemia in rats: modulation of the hepatic carbohydrate response element-binding protein-mediated pathway Evid-Based Complement Altern Med 2012 2012 10.1155/2012/570948
K. Iizuka B. Miller K. Uyeda Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice Am J Physiol Endocrinol Metab 2006 291 2 E358 364 1:CAS:528:DC%2BD28XovVWgt7c%3D 16705063 10.1152/ajpendo.00027.2006
Y. Li V.H. Tran B.P. Kota S. Nammi C.C. Duke B.D. Roufogalis Preventative effect of Zingiber officinale on insulin resistance in a high-fat high-carbohydrate diet-fed rat model and its mechanism of action Basic Clin Pharmacol Toxicol 2014 115 2 209 215 1:CAS:528:DC%2BC2cXhtFCktrbE 24428842 10.1111/bcpt.12196
X.H. Li K.C.Y. McGrath V.H. Tran Y.M. Li C.C. Duke B.D. Roufogalis et al. Attenuation of proinflammatory responses by S-[6]-gingerol via inhibition of ROS/NF-Kappa B/COX2 activation in HuH7 cells Evid Based Complement Alternat Med 2013 2013 23843863 3697228 10.1155/2013/146142
N. Kota V.V. Panpatil R. Kaleb B. Varanasi K. Polasa Dose-dependent effect in the inhibition of oxidative stress and anticlastogenic potential of ginger in STZ induced diabetic rats Food Chem 2012 135 4 2954 2959 1:CAS:528:DC%2BC38XhtlaktLzL 22980896 10.1016/j.foodchem.2012.06.116
J. Wang W. Ke R. Bao X. Hu F. Chen Beneficial effects of ginger Zingiber officinale Roscoe on obesity and metabolic syndrome: a review: beneficial effects of ginger in metabolic syndrome Ann N Y Acad Sci 2017 1398 1 83 98 28505392 10.1111/nyas.13375
J. Ahn H. Lee C.H. Jung S.Y. Ha H.D. Seo Y.I. Kim et al. 6-Gingerol ameliorates hepatic steatosis via HNF4α/miR-467b-3p/GPAT1 cascade Cell Mol Gastroenterol Hepatol 2021 12 4 1201 1213 1:CAS:528:DC%2BB38XhtlSrur%2FN 34139323 8445893 10.1016/j.jcmgh.2021.06.007
J. Li S. Wang L. Yao P. Ma Z. Chen T.L. Han et al. 6-Gingerol ameliorates age-related hepatic steatosis: association with regulating lipogenesis, fatty acid oxidation, oxidative stress, and mitochondrial dysfunction Toxicol Appl Pharmacol 2019 362 125 135 1:CAS:528:DC%2BC1cXitF2qtLvF 30408433 10.1016/j.taap.2018.11.001
X.J. Chen W.J. Liu M.L. Wen H. Liang S.M. Wu Y.Z. Zhu et al. Ameliorative effects of compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats Sci Rep 2017 7 1 41144 1:CAS:528:DC%2BC2sXhsFamsr4%3D 28106137 5247696 10.1038/srep41144
S.Y. Choi J.S. Park C.H. Shon C.Y. Lee J.M. Ryu D.J. Son et al. Fermented Korean red ginseng extract enriched in Rd and Rg3 protects against non-alcoholic fatty liver disease through regulation of mTORC1 Nutrients 2019 11 12 2963 31817227 6949916 10.3390/nu11122963
Y.C. Hwang D.H. Oh M.C. Choi S.Y. Lee K.J. Ahn H.Y. Chung et al. Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats Korean J Intern Med 2018 33 2 347 355 1:CAS:528:DC%2BC1MXhsVKrsb%2FI 28142230 10.3904/kjim.2015.208
M. Kim K. Lee T.J. Iseli A.J. Hoy J. George T. Grewal et al. Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes Liver Int 2013 33 10 1583 1593 1:CAS:528:DC%2BC3sXhs1Slsr7N 23998390 10.1111/liv.12287
C. Yue D. Li S. Fan F. Tao Y. Yu W. Lu et al. Long-term and liver-selected ginsenoside C-K nanoparticles retard NAFLD progression by restoring lipid homeostasis Biomaterials 2023 301 1:CAS:528:DC%2BB3sXhslens73P 37619263 10.1016/j.biomaterials.2023.122291
E. Bessell N.R. Fuller T.P. Markovic J. Burk T. Picone C. Hendy et al. Effects of alpha-cyclodextrin on cholesterol control and compound K on glycaemic control in people with pre-diabetes: protocol for a phase III randomized controlled trial Clin Obes 2019 9 4 31172667 10.1111/cob.12324
K. Kim M. Park Y.M. Lee M.R. Rhyu H.Y. Kim Ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI-H716 cells via bile acid receptor activation Arch Pharm Res 2014 37 9 1193 1200 1:CAS:528:DC%2BC2cXjsVCht7c%3D 24590628 10.1007/s12272-014-0362-0
J. Wu G. Huang Y. Li X. Li Flavonoids from Aurantii fructus Immaturus and Aurantii fructus: promising phytomedicines for the treatment of liver diseases Chin Med 2020 15 1 89 1:CAS:528:DC%2BB3cXhslSmurbN 32863858 7449045 10.1186/s13020-020-00371-5
L. Pari A. Karthikeyan P. Karthika A. Rathinam Protective effects of hesperidin on oxidative stress, dyslipidaemia and histological changes in iron-induced hepatic and renal toxicity in rats Toxicol Rep 2015 2 46 55 1:CAS:528:DC%2BC2MXmtlejsr0%3D 28962336 10.1016/j.toxrep.2014.11.003
A. Jain A. Yadav A.I. Bozhkov V.I. Padalko S.J.S. Flora Therapeutic efficacy of silymarin and naringenin in reducing arsenic-induced hepatic damage in young rats Ecotoxicol Environ Saf 2011 74 4 607 614 1:CAS:528:DC%2BC3MXlvVeqtL8%3D 20719385 10.1016/j.ecoenv.2010.08.002
Q. Xie S. Gao M. Lei Z. Li Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease Aging 2022 14 3 1265 1279 1:CAS:528:DC%2BB38XhsFKmtLnJ 35143415 8876922 10.18632/aging.203817
H. Chen T. Nie P. Zhang J. Ma A. Shan Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation Life Sci 2022 296 1:CAS:528:DC%2BB38Xlt12qt7o%3D 35218767 10.1016/j.lfs.2022.120428
S.W. Wang H. Sheng Y.F. Bai Y.Y. Weng X.Y. Fan L.J. Lou et al. Neohesperidin enhances PGC-1α-mediated mitochondrial biogenesis and alleviates hepatic steatosis in high fat diet fed mice Nutr Diabetes 2020 10 1 27 1:CAS:528:DC%2BB3cXhsFyktrfN 32759940 7406515 10.1038/s41387-020-00130-3
M. Cheraghpour H. Imani S. Ommi S.M. Alavian E. Karimi-Shahrbabak M. Hedayati et al. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled, double-blind clinical trial Phytother Res 2019 33 8 2118 2125 1:CAS:528:DC%2BC1MXhsFWrt7bI 31264313 10.1002/ptr.6406
Z. Yari M. Cheraghpour S.M. Alavian M. Hedayati H. Eini-Zinab A. Hekmatdoost The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial Eur J Clin Nutr 2020 75 1 99 111 32647367 10.1038/s41430-020-0679-3
K. Baxter S. Driver E. Williamson Stockley’s herbal medicines interactions 2013 London Pharmaceutical Press
J. Jayaraman V.A.S. Jesudoss V.P. Menon N. Namasivayam Anti-inflammatory role of naringenin in rats with ethanol induced liver injury Toxicol Mech Methods 2012 22 7 568 576 1:CAS:528:DC%2BC38Xht1ajsrfK 22900548 10.3109/15376516.2012.707255
Z. Namkhah F. Naeini S. Mahdi Rezayat M. Yaseri S. Mansouri M. Javad Hosseinzadeh-Attar Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial Int J Clin Pract 2021 75 11 1:CAS:528:DC%2BB3MXis1ars73J 34516703 10.1111/ijcp.14852
S.F. AbouZid H.S. Ahmed A.S. Moawad A.I. Owis S.N. Chen A. Nachtergael et al. Chemotaxonomic and biosynthetic relationships between flavonolignans produced by Silybum marianum populations Fitoterapia 2017 119 175 184 1:CAS:528:DC%2BC2sXovVKmtbo%3D 28392269 5532885 10.1016/j.fitote.2017.04.002
S.F. AbouZid H.S. Ahmed A.E.M.A. Abd El Mageed A.S. Moawad A.I. Owis S.N. Chen et al. Linear regression analysis of silychristin A, silybin A and silybin B contents in Silybum marianum Nat Prod Res 2020 34 2 305 310 1:CAS:528:DC%2BC1cXisVGnurzN 30488719 10.1080/14786419.2018.1527838
A. Cicero A. Colletti S. Bellentani Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence Nutrients 2018 10 9 1153 30142943 6163782 10.3390/nu10091153
A. Di Costanzo R. Angelico Formulation strategies for enhancing the bioavailability of silymarin: the state of the art Molecules 2019 24 11 2155 31181687 6600503 10.3390/molecules24112155
A. Semalty M. Semalty M.S.M. Rawat F. Franceschi Supramolecular phospholipids–polyphenolics interactions: the PHYTOSOME® strategy to improve the bioavailability of phytochemicals Fitoterapia 2010 81 5 306 314 1:CAS:528:DC%2BC3cXmvVWnsbs%3D 19919847 10.1016/j.fitote.2009.11.001
I. Grattagliano C.V. Diogo M. Mastrodonato O. de Bari M. Persichella D.Q.H. Wang et al. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes World J Gastroenterol 2013 19 20 3007 3017 1:CAS:528:DC%2BC3sXptFygsrc%3D 23716980 3662940 10.3748/wjg.v19.i20.3007
Y. Haddad D. Vallerand A. Brault P.S. Haddad Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis Evid Based Complement Alternat Med 2011 2011 19884114 3136786 10.1093/ecam/nep164
K.D. Kim H.J. Lee S.P. Lim M.D.A. Sikder S.Y. Lee C.J. Lee Silibinin regulates gene expression, production and secretion of mucin from cultured airway epithelial cells Phytother Res 2012 26 9 1301 1307 1:CAS:528:DC%2BC38XhtlSmt7rK 22275269 10.1002/ptr.3727
F. Salamone F. Galvano F. Cappello A. Mangiameli I. Barbagallo V.G. Li Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis Transl Res J Lab Clin Med 2012 159 6 477 486 1:CAS:528:DC%2BC38Xnsl2lsr0%3D
F. Salamone F. Galvano A. Marino Gammazza A. Marino C. Paternostro D. Tibullo et al. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis Dig Liver Dis 2012 44 4 334 342 1:CAS:528:DC%2BC38Xjs1Giu7k%3D 22197629 10.1016/j.dld.2011.11.010
G. Serviddio F. Bellanti A.M. Giudetti G.V. Gnoni A. Petrella R. Tamborra et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis J Pharmacol Exp Ther 2010 332 3 922 932 1:CAS:528:DC%2BC3cXivFCjs7o%3D 20008062 10.1124/jpet.109.161612
J. Yao M. Zhi X. Gao P. Hu C. Li X. Yang Effect, and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol 2013 46 3 270 277 10.1590/1414-431X20122551
J. Yao M. Zhi C. Minhu Effect of silybin on high-fat-induced fatty liver in rats Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol 2011 44 7 652 659 1:CAS:528:DC%2BC3MXht1WgtbzE
S. Zhong Y. Fan Q. Yan X. Fan B. Wu Y. Han et al. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: a meta-analysis (PRISMA) of randomized control trials Medicine (Baltimore) 2017 96 49 1:CAS:528:DC%2BC1cXhtF2lurs%3D 29245314 10.1097/MD.0000000000009061
T. Chantarojanasiri Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report Drugs Context 2023 12 1 5 10.7573/dic.2023-1-4
A. Hashem Silymarin and management of liver function in nonalcoholic steatohepatitis: a case report Drugs Context 2023 12 1 5 10.7573/dic.2023-2-9
L. Zhong W. Lyu Z. Lin J. Lu Y. Geng L. Song et al. Quinoa ameliorates hepatic steatosis, oxidative stress, inflammation and regulates the gut microbiota in nonalcoholic fatty liver disease rats Foods 2023 12 9 1780 1:CAS:528:DC%2BB3sXhtVartbzE 37174318 10178724 10.3390/foods12091780
S.H. Mirhashemi A. Hakakzadeh F.E. Yeganeh B. Oshidari S.P. Rezaee Effect of 8 weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery Metab Open 2022 14 10.1016/j.metop.2022.100190
J.E. Poulos P.T. Kalogerinis V. Milanov C.T. Kalogerinis E.J. Poulos The effects of vitamin E, silymarin and carnitine on the metabolic abnormalities associated with nonalcoholic liver disease J Diet Suppl 2021 19 3 287 302 33491528 10.1080/19390211.2021.1874587
Y. Yao X. Yang Z. Shi G. Ren Anti-inflammatory activity of saponins from quinoa (Chenopodium quinoa Willd.) seeds in lipopolysaccharide-stimulated RAW 264.7 macrophages cells J Food Sci 2014 79 5 H1018 H1023 1:CAS:528:DC%2BC2cXns1Squrk%3D 24712559 10.1111/1750-3841.12425
T. An J.X. Liu X.Y. Yang B.H. Lv Y.X. Wu G.J. Jiang Supplementation of quinoa regulates glycolipid metabolism and endoplasmic reticulum stress in the high-fat diet-induced female obese mice Nutr Metab 2021 18 1 1 11 10.1186/s12986-021-00622-8
M.M. Al-Qabba M.A. El-Mowafy S.A. Althwab H.A. Alfheeaid T. Aljutaily H. Barakat Phenolic profile, antioxidant activity, and ameliorating efficacy of Chenopodium quinoa sprouts against CCl4-induced oxidative stress in rats Nutrients 2020 12 10 2904 1:CAS:528:DC%2BB3cXitlyjtbnM 32977429 7598205 10.3390/nu12102904
N. Shen T. Wang Q. Gan S. Liu L. Wang B. Jin Plant flavonoids: classification, distribution, biosynthesis, and antioxidant activity Food Chem 2022 383 1:CAS:528:DC%2BB38XmslSlsr4%3D 35413752 10.1016/j.foodchem.2022.132531
F.G. De Carvalho P.P. Ovídio G.J. Padovan A.A. Jordão Junior J.S. Marchini A.M. Navarro Metabolic parameters of postmenopausal women after quinoa or corn flakes intake—a prospective and double-blind study Int J Food Sci Nutr 2013 65 3 380 385 24344670 10.3109/09637486.2013.866637
D. Navarro-Perez J. Radcliffe A. Tierney M. Jois Quinoa seed lowers serum triglycerides in overweight and obese subjects: a dose-response randomized controlled clinical trial Curr Dev Nutr 2017 1 9 29955719 5998774 10.3945/cdn.117.001321
A. Foucault V. Mathé R. Lafont P. Even W. Dioh S. Veillet et al. Quinoa extract enriched in 20-hydroxyecdysone protects mice from diet-induced obesity and modulates adipokines expression Obesity 2012 20 2 270 277 1:CAS:528:DC%2BC38XhsFCmt74%3D 21869758 10.1038/oby.2011.257
B.L. Graf A. Poulev P. Kuhn M.H. Grace M.A. Lila I. Raskin Quinoa seeds leach phytoecdysteroids and other compounds with anti-diabetic properties Food Chem 2014 163 178 185 1:CAS:528:DC%2BC2cXps12mt74%3D 24912714 4116738 10.1016/j.foodchem.2014.04.088
A.S. Foucault P. Even R. Lafont W. Dioh S. Veillet D. Tomé et al. Quinoa extract enriched in 20-hydroxyecdysone affects energy homeostasis and intestinal fat absorption in mice fed a high-fat diet Physiol Behav 2014 128 226 231 1:CAS:528:DC%2BC2cXkslGktb4%3D 24534167 10.1016/j.physbeh.2014.02.002
T.G. Simnadis L.C. Tapsell E.J. Beck Physiological effects associated with quinoa consumption and implications for research involving humans: a review Plant Foods Hum Nutr 2015 70 3 238 249 1:CAS:528:DC%2BC2MXhtlCjs7nP 26249220 10.1007/s11130-015-0506-5